Wróć

Wybierz swój region

Corporate

Umów konsultację o krwi pępowinowej

Umawiam

Terapie
komórkami macierzystymi

Terapie komórkami macierzystymi

Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).

Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.

Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.

Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.

Data aktualizacji: 11.2026

Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord

Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
Lp. Źródło Typ źródła Wskazanie Obszar medycyny Rok podania Terapia Kraj Wiek odbiorcy
1 Skeletal Muscle Allogeneic – Related Duchenne Muscular Dystrophy (DMD) Genetic Disorder 2026 Experimental Therapy Poland 14
2 Skeletal Muscle Allogeneic – Related Dystrophia Progressiva Pseudohypertrophica/DMD Genetic Disorders 2026 Experimental Therapy Poland 0
3 Skeletal Muscle Allogeneic – Related Dystrophia Progressiva Pseudohypertrophica/DMD Genetic Disorders 2026 Experimental Therapy Poland 0
4 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 4
5 Cord Tissue Autologous Autism Neurology 2026 Experimental Therapy Slovakia 4
6 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 7
7 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 5
8 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 7
9 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 3
10 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2026 Experimental Therapy Poland 67
11 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2026 Experimental Therapy Poland 50
12 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 4
13 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 6
14 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 6
15 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 6
16 Cord Tissue Allogeneic – Unrelated GvHD Hematology 2026 Experimental Therapy Poland 2
17 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 3
18 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2026 Experimental Therapy Poland 60
19 Cord Tissue Allogeneic – Unrelated GvHD Hematology 2026 Experimental Therapy Poland 5
20 Cord Tissue Allogeneic Autism Neurology 2026 Experimental Therapy United Arab Emirates 6
21 Cord Tissue Allogeneic – Unrelated GvHD Hematology 2026 Experimental Therapy Poland 4
22 Cord Tissue Allogeneic – Unrelated Cerebral palsy Neurology 2026 Experimental Therapy Poland 4
23 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 8
24 Cord Tissue Allogeneic – Unrelated Cerebral palsy Neurology 2026 Experimental Therapy Poland 3
25 Cord Tissue Autologous Cerebral Palsy Neurology 2026 Experimental Therapy Slovakia 2
26 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 6
27 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 13
28 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 8
29 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 9
30 Cord Tissue Autologous Autism Neurology 2026 Experimental Therapy Slovakia 8
31 Cord Tissue Autologous Autism Neurology 2026 Experimental Therapy Slovakia 5
32 Cord Tissue Autologous Autism Neurology 2026 Experimental Therapy Slovakia 3
33 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 3
34 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 7
35 Cord Tissue Allogeneic – Unrelated Optic Atrophy Ophthalmology 2026 Experimental Therapy Poland 76
36 Cord Tissue Allogeneic – Unrelated Encephalitis, Myelitis Neurology 2026 Experimental Therapy Poland 36
37 Cord Tissue Allogeneic – Unrelated Stress Incontinence Urology 2026 Experimental Therapy Poland 62
38 Cord Tissue Allogeneic – Unrelated aGvHD, PNH Hematology 2026 Experimental Therapy Poland 17
39 Cord Tissue Allogeneic – Unrelated Progressive Bulbar Palsy Neurology 2026 Experimental Therapy Poland 58
40 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 6
41 Cord Tissue Allogeneic – Unrelated Spinocerebellar Ataxia Neurology 2026 Experimental Therapy Poland 59
42 Cord Tissue Allogeneic – Unrelated aGvHD Hematology 2026 Experimental Therapy Poland 15
43 Cord Tissue Allogeneic – Unrelated aGvHD Hematology 2026 Experimental Therapy Poland 12
44 Cord Tissue Allogeneic – Unrelated aGvHD Hematology 2026 Experimental Therapy Poland 10
45 Cord Tissue Allogeneic – Unrelated MSA, Multiple System Atrophy Neurology 2026 Experimental Therapy Centrum Medyczne Klara Częstochowa 53
46 Cord Tissue Allogeneic – Unrelated Stress Incontinence Gynecology 2026 Experimental Therapy Szpital Uniwersytecki w Krakowie ul. Mikołaja Kopernika 79
47 Cord Tissue Allogeneic – Unrelated Progressive Bulbar Palsy Neurology 2026 Experimental Therapy Centrum Medyczne Klara Częstochowa 65
48 Cord Tissue Allogeneic – Unrelated MSA, Multiple System Atrophy Neurology 2026 Experimental Therapy Centrum Medyczne Klara Częstochowa 61
49 Cord Tissue Allogeneic Related Spondylosis + Lumbar Disc Disease Rheumatology 2026 Experimental Therapy Slovakia , Malacky 32
50 Cord Tissue Autologus Autism Neurology 2026 Experimental Therapy Slovakia , Malacky 3
51 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedy 2026 Experimental Therapy Poland 64
52 Cord Tissue Allogeneic – Unrelated Stress Incontinence Gynecology 2026 Experimental Therapy Poland 75
53 Cord Tissue Allogeneic – Unrelated Polyneuropathy Neurology 2026 Experimental Therapy Poland 27
54 Cord Tissue Allogeneic – Unrelated Acute And Chronic Graft-Versus-Host-Disease aGVHD And cGVHD Hematology 2026 Experimental Therapy Poland 17
55 Cord Tissue Allogeneic – Unrelated Acute and chronic Graft-versus-Host-Disease aGvHD and cGvHD Hematology 2026 Experimental Therapy Poland 3
56 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 4
57 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 8
58 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 5
59 Cord Blood Allogeneic – Unrelated Acute Leukemia in remission, Pancytopenia after treatment Hematology 2026 Standard Therapy Denmark 18
60 Cord Blood Allogeneic – Related Juvenile Myelomonocytic Leukemia (JMML) Hematology 2026 Standard Therapy Germany 10
61 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 6
62 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 7
63 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 5
64 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 4
65 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 8
66 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 7
67 Cord Blood Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Turkey 7
68 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 8
69 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 4
70 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 3
71 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 8
72 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 5
73 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 3
74 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 6
75 Cord Blood Allogeneic – Related Diamond-Blackfan Anemia (DBA) Hematology 2026 Standard Therapy Germany 10
76 Cord Blood Autologus Autism Neurology 2026 Experimental Therapy Poland, Lublin, Uniwersytecki Szpital Kliniczny 7
77 Cord Blood Autologus Autism Neurology 2026 Experimental Therapy Poland, Lublin, Uniwersytecki Szpital Kliniczny 7
78 Cord Blood Autologus Autism Neurology 2026 Experimental Therapy Slovakia , Malacky 3
79 Cord Blood Allogeneic – Related Thalassemia Beta Hematology 2026 Standard therapy Turkey 8
80 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 5
81 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 11
82 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 6
83 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 7
84 Bone Marrow Family Allogeneic T-Cell Lymphoma Hematology 2026 Standard Therapy Netherlands 65
85 Bone Marrow Family Allogeneic Other Malignancy Hematology 2026 Standard Therapy France 51
86 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 27
87 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 14
88 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 68
89 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 43
90 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
91 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 69
92 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 67
93 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 64
94 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 73
95 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 26
96 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
97 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 66
98 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Romania 25
99 Bone Marrow Family Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 65
100 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Poland 62